Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketorolac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.97 |
| ▸ | CDC42 | P60953 | 3/20 | 0.97 |
| ▸ | RAC1 | P63000 | 3/20 | 0.97 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.97 |
| ▸ | NPC1 | O15118 | 2/20 | 0.97 |
| ▸ | RAB9A | P51151 | 2/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | CA4 | P22748 | 5/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketorolac SCHEMBL14891 | 0.98 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL23466702 | 0.98 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL4103 | 0.98 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL14892 | 0.98 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28480507 | 0.97 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL15661224 | 0.97 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28472361 | 0.97 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL20553125 | 0.97 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL5301763 | 0.97 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL28826490 | 0.97 | PTGS2 (0.97) | PTGS2CDC42RAC1PTGS1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181215-B | Preparation method of ketorolac or related impurities of ketorolac salt | 四川仁安药业有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-114181215-A | Preparation method of related impurities of ketorolac or ketorolac salt | 四川仁安药业有限责任公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20180311177-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent and Methods of Making and Using Same | PFIZER INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3368021-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075369-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311177-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent and Methods of Making and Using Same | CD44, TP53, TSG101 | PTGS2 3625/4885PTGS1 3674/4885CDC42 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.